Skip to main content

Table 3 Correlation of GPC3 expression with the clinical phenotypes of lung adenocarcinoma (LUAD) samples

From: GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma

Characteristics Variable Number of patients GPC3 expression Test P value
High Percent (%) Low Percent (%)
Age ≥ 65 310 146 55.9 164 53.8 Wilcoxon 0.1332
  < 65 256 115 44.1 141 46.2   
Location Central Lung 67 29 39.2 38 30.9 Wilcoxon 0.2896
  Peripheral Lung 130 45 60.8 85 69.1   
years_smoked ≥ 41 160 105 62.5 129 57.1 Wilcoxon 0.5824
  < 41 234 63 37.5 97 42.9   
pathologic_M M0 394 1 0.4 1 0.3 Kruskal 0.7793
  M1 20 3 1.1 2 0.6   
  M1a 2 6 2.3 14 4.4   
  M1b 5 176 66.7 218 69.2   
  MX 158 78 29.5 80 25.4   
pathologic_N N0 371 14 5.2 3 1 Kruskal 0.0141
  N1 107 177 65.8 194 61.6   
  N2 87 38 14.1 69 21.9   
  N3 2 39 14.5 48 15.2   
  NX 17 1 0.4 1 0.3   
pathologic_T T1 82 24 8.9 25 7.9 Kruskal 0.0002
  T1a 49 34 12.6 26 8.3   
  T1b 60 34 12.6 55 17.5   
  T2 203 4 1.5 16 5.1   
  T2a 89 14 5.2 15 4.8   
  T2b 29 91 33.7 112 35.6   
  T3 50 16 5.9 34 10.8   
  T4 20 51 18.9 31 9.8   
  TX 3 2 0.7 1 0.3   
Radiation therapy Yes 69 33 13.9 36 13.9 Wilcoxon 0.4830
  No 428 205 86.1 223 86.1   
Gender Female 316 110 40.7 159 50.5 Wilcoxon 0.0027
  Male 269 160 59.3 156 49.5   
Tumor stage I 316 163 61.5 153 49.2 Kruskal 0.0435
  II 135 11 4.2 17 5.5   
  III 97 50 18.9 85 27.3   
  IV 28 41 15.5 56 18